Drugs / Domperidone
Domperidone
Trials 38
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02816853 | May → Aug 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01643889 | Jul → Nov 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00103597 | Jan → Sep 2005 | Parkinson disease, multiple system atrophy, orthostatic hypotension | Royal Brisbane and Women's Hospital | Completed | No outcome recorded |
| Phase 26 trials · 2 missed | ||||||
| Phase 2 | NCT02493049 | Aug 2015 → Feb 2019 | relapsing-remitting multiple sclerosis | University of Calgary | Completed | Missed primary |
| Phase 2 | NCT02308137 | Feb 2015 → Jan 2020 | secondary progressive multiple sclerosis | University of Calgary | Completed | Missed primary |
| Phase 2 | NCT00760461 | Oct 2008 → Jul 2011 | gastroparesis | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00284024 | Sep 2006 → Sep 2007 | — | Hamilton Health Sciences Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00305331 | Mar 2006 → Jul 2008 | Parkinson disease | University Health Network, Toronto | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00238056 | — | pulmonary immaturity | Nantes University Hospital | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04802785 | Jun → Jul 2021 | — | Dinara Zhumanbayeva | Unknown | No outcome recorded |
| Phase 2/3 | NCT00308334 | Oct 2003 → Dec 2007 | — | IWK Health Centre | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT06695962 | Mar 2026 → Jun 2029 expected | type 1 diabetes mellitus | University Hospital, Rouen | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02699385 | Dec 2015 → Aug 2017 | gastroenteritis | Janssen-Cilag International NV | Terminated | No outcome recorded |
| Phase 3 | NCT01710462 | Aug 2013 → ? | gastroesophageal reflux disease | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01878526 | Jun 2013 → Aug 2015 | gastroesophageal reflux disease, systemic sclerosis | Khon Kaen University | Completed | No outcome recorded |
| Phase 3 | NCT01696734 | Oct 2012 → Oct 2027 expected | dyspepsia, esophagitis, gastroesophageal reflux disease, gastroparesis | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01378884 | Mar 2010 → Mar 2012 | gastroparesis | Allegiance Health | Withdrawn | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT04583111 | Mar 2020 → Mar 2022 | — | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03617016 | Aug 2018 → Jul 2020 | dyspepsia | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03355170 | Mar → Dec 2018 | gastroesophageal reflux disease, heart disorder | Neutec Ar-Ge San ve Tic A.Ş | Withdrawn | No outcome recorded |
| Phase 4 | NCT02980250 | Nov 2015 → May 2017 | stomach disorder | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02958046 | Jan 2014 → May 2015 | gastroesophageal reflux disease | Neutec Ar-Ge San ve Tic A.Ş | Completed | No outcome recorded |
| Phase 4 | NCT02685436 | Mar 2013 → May 2015 | gastroesophageal reflux disease | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase not applicable8 trials · 1 missed | ||||||
| — | NCT03662113 | Nov 2017 → Nov 2018 | — | Children's Hospital of Fudan University | Completed | Missed primary |
| — | NCT04699591 | Apr 2013 → Dec 2035 expected | gastroesophageal reflux disease, gastroparesis | Jose Cocjin | Recruiting | No outcome recorded |
| — | NCT01780909 | Feb → Dec 2013 | — | KU Leuven | Unknown | No outcome recorded |
| — | NCT01711918 | Jul 2012 → Apr 2014 | idiopathic gastroparesis | Ron Schey | Completed | No outcome recorded |
| — | NCT00777439 | Oct 2008 → Jan 2017 | gastroparesis | Arnold, George, M.D. | Unknown | No outcome recorded |
| — | NCT00761254 | Aug 2008 → Sep 2012 | constipation disorder, dyspepsia, esophagitis, gastroesophageal reflux disease +1 | Carle Physician Group | Terminated | No outcome recorded |
| — | NCT01347814 | Feb 2008 → Apr 2010 | diabetes mellitus | University of Limerick | Completed | No outcome recorded |
| — | NCT00552422 | Mar 2007 → Sep 2010 | gastroesophageal reflux disease, gastroparesis | David J. Lederer, M.D. | Terminated | No outcome recorded |
| Phase not stated7 trials | ||||||
| — | NCT02567175 | — | constipation disorder, gastroesophageal reflux disease, gastroparesis, intestinal pseudo-obstruction | Prasanna K Kapavarapu | No longer available | No outcome recorded |
| — | NCT02227927 | — | gastroesophageal reflux disease, gastroparesis | Scott Gabbard, MD | No longer available | No outcome recorded |
| — | NCT02757534 | — | gastroparesis | Yehudith Assouline-Dayan | No longer available | No outcome recorded |
| — | NCT03810287 | — | gastroparesis | Yale University | No longer available | No outcome recorded |
| — | NCT02494687 | — | idiopathic gastroparesis | Eastern Regional Medical Center | Available | No outcome recorded |
| — | NCT04996134 | — | gastroparesis | Wake Forest University Health Sciences | No longer available | No outcome recorded |
| — | NCT03128398 | — | gastroparesis | Palo Alto Medical Foundation | No longer available | No outcome recorded |
| Comparator or background therapy17 trials | ||||||
| Phase 0 | NCT03221855 Comparator | Mar 2013 → Dec 2015 | — | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 1 | NCT01021475 Comparator | Nov 2009 → Nov 2010 | dyspepsia | International College of Osteopathic Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT05596006 Comparator | Dec 2022 → Mar 2023 | — | Gadjah Mada University | Completed | No outcome recorded |
| Phase 2 | NCT01512225 Comparator | May 2012 → Oct 2015 | — | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 2 | NCT00006077 Background | Aug 2000 → Jul 2003 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 3 | NCT05570292 Comparator | Oct 2022 → Apr 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT01257672 Comparator | Jul 2011 → Nov 2013 | gastroenteritis | IRCCS Burlo Garofolo | Completed | No outcome recorded |
| Phase 3 | NCT01355276 Comparator | Oct 2010 → Jun 2011 | dyspepsia | Eisai Inc. | Completed | Met primary |
| Phase 4 | NCT07578402 Comparator | May → Dec 2026 expected | dyspepsia | Rakibul Mostafa | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05030116 Comparator | Jun 2019 → May 2020 | dyspepsia | Ruijin Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03806062 Comparator | Jan → Dec 2018 | lactation disease | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02264587 Comparator | Oct 2014 → Sep 2015 | gastroparesis | Liangzhou Wei | Unknown | No outcome recorded |
| Phase 4 | NCT02140073 Comparator | Dec 2013 → Jun 2014 | gastroesophageal reflux disease | Belarusian Medical Academy of Post-Graduate Education | Unknown | No outcome recorded |
| Phase 4 | NCT03022201 Comparator | May 2013 → May 2016 | Parkinson disease | Seoul National University Hospital | Completed | Met primary |
| — | NCT04104867 Comparator | Sep 2019 → Oct 2022 | — | Mahidol University | Unknown | No outcome recorded |
| — | NCT00874133 Comparator | Mar 2009 → Dec 2013 | gastroparesis | Rabin Medical Center | Terminated | No outcome recorded |
| — | NCT00604942 Background | Nov 2007 → Oct 2010 | achalasia, gastroesophageal reflux disease | Guy's and St Thomas' NHS Foundation Trust | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 55 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Domperidone | “0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.” NCT02980250 ↗ |
| Known as | Domperidone / Motilium | “Domperidone / Motilium” NCT01378884 ↗ |
| Known as | Domperidone Suspension(Motilium), B12200018238 | “Domperidone Suspension(Motilium), B12200018238” NCT02980250 ↗ |
| Known as | Motilium | “compare Cinitapride tablets with domperidone tablets (motilium), and to evaluate the efficacy and safety of Cinitapride tablets in the treatment of mild to moderate functional...” NCT01355276 ↗2“2 tablets of Motilium® (API: domperidone 10 mg) 20 minutes before the intake of Gabbroral® oral tablet formulation” NCT01780909 ↗ |
| Action | Inhibit | “Domperidone, a drug that enhances upper gastric motility, is an anti-dopaminergic medication that also elevates prolactin levels.” NCT00308334 ↗ |
| Route | Oral | “10 mg po TID X 14 days” NCT00308334 ↗ |